Search

Displaying results 5261 - 5270 of 10000 in total
  1. Drug

    ALKS 29

    go.drugbank.com/drugs/DB05723
    Experimental

    ALKS 29 is a new product candidate for the treatment of alcohol dependence. It is being developed by Alkermes, Inc.

  2. Drug

    IDD-1

    go.drugbank.com/drugs/DB05439
    Experimental

    Eladem (IDD-1) is a therapeutic vaccine consisting of dendritophages that are loaded in vitro with tumor antigens and then reinjected into the subject. … As with other monoclonal antibodies, this process stimulates an immune response to a particular disease-related antigen.

  3. Drug

    Cat dander extract

    go.drugbank.com/drugs/DB13904
    Approved

    It is used in the diagnosis and treatment (immunotherapy) of patients with a history of allergy to cats. … Cat dander extract can be used in immunotherapy in individuals who cannot avoid exposure to cat allergens to initiate hyposensitization.

  4. Drug

    OT-551

    go.drugbank.com/drugs/DB05650
    Investigational

    OT-551 is a novel small molecule that is topically dosed in an eye drop and has the unique ability to penetrate cell membranes and reach both the front and the back of the eye. … It is intended to treat Age-related macular Degeneration (AMD), and preclinical research results indicate additional uses for OT-551, including treatment of early stage and advanced dry age-related macular

  5. Drug

    Meticrane

    go.drugbank.com/drugs/DB13284
    Approved

    Meticrane is a diuretic medication. It has been marketed in Japan under the trade name Arresten and is used to lower blood pressure [L5647].

  6. Drug

    Guanoxan

    go.drugbank.com/drugs/DB13211
    Approved

    Guanoxan is an antihypertensive agent similar in its mechanism of action to guanethidine; may cause liver damage. … Guanoxan was approved in the UK but was withdrawn from the market due to hepatotoxicity.

  7. Drug

    Potassium carbonate

    go.drugbank.com/drugs/DB13977
    Approved

    Potassium carbonate (K2CO3) is a white salt, soluble in water (insoluble in ethanol) which forms a strongly alkaline solution. … It can be made as the product of potassium hydroxide's absorbent reaction with carbon dioxide. It presents a large capacity to absorb moisture.

  8. Drug

    Lemzoparlimab

    go.drugbank.com/drugs/DB17572
    Investigational

    Lemzoparlimab is under investigation in clinical trial NCT04912063 (Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or … IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome).

  9. Drug

    SC12267

    go.drugbank.com/drugs/DB05125
    Investigational

    SC12267 is a novel, small molecule agent from the class of DMARDs (disease modifying anti-rheumatic drug) for the therapy of autoimmune diseases such as rheumatoid arthritis or multiple sclerosis. … Through highly selective inhibition of pyrimidine biosynthesis, it controls the growth of rapidly proliferating cells, especially of lymphocytes, which are important for the immune response.

  10. Drug

    Liposomal prostaglandin E1

    go.drugbank.com/drugs/DB05391
    Investigational

    The liposomal formulation of PGE-1 changes the drug’s dynamics and improve its therapeutic index in ways that PGE-1 alone could not achieve. … Liposome-encapsulated form of prostaglandin E1 (Liprostin) is known to be a potent vasodilator and platelet inhibitor as well as an anti-inflammatory and anti-thrombotic agent.